Virtual Medicine Grand Rounds – Matthew Cavender, MD, & Amy Mottl, MD, – “SGLT2i as Cardiorenal Protection”

Dr. Cavender is an active interventional cardiologist with a focus on catheter based interventions for coronary artery disease, aortic and mitral valve disease, peripheral vascular disease, and cardiogenic shock. In addition to his clinical interests, he has an active research program with an emphasis on improving the quality of health care delivery and understanding the clinical effectiveness of pharmacological and device based therapies for patients with coronary artery disease, diabetes, peripheral arterial disease, and valvular heart disease.

Dr. Mottl’s research has involved investigation of genetic and epidemiologic risk factors of chronic kidney disease, with an emphasis on diabetic kidney disease. She is especially interested in pathogenic mechanisms of diabetic nephropathy and how these may vary between those with and without proteinuria. She is being funded through 2017, by a career development award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study whether there are different pathologic and clinical manifestations of diabetes on the kidney and how these relate to diabetic complications of the eye. Dr. Mottl is a renal consultant to the multicenter, NIH and CDC funded study: ‘SEARCH for Diabetes in Youth’ which is an epidemiologic cohort of children with type 1 or 2 diabetes. One of the fundamental aims of this study is to track the incidence, risk factors and natural history of microvascular complications of diabetes diagnosed during childhood. Dr. Mottl’s long-term goal is to elucidate pathogenic mechanisms in diabetic microvascular complications for the purpose of targeting novel therapies.